Zobrazeno 1 - 10 of 30 pro vyhledávání: '"Christopher T. Gubish"'
3
Supplementary Figure 2 from c-Src Activation Mediates Erlotinib Resistance in Head and Neck Cancer by Stimulating c-Met
Autor: Jennifer R. Grandis, Jill M. Siegfried, Kelly M. Quesnelle, Sonali Joyce, Christopher T. Gubish, Cassandra Henry, Sufi M. Thomas, Vivian Wai Yan Lui, Guoqing He, Laura P. Stabile
PDF file - 36K, After 48 hrs of incubation, the conditioned media was harvested from normal lung fibroblasts (NLFB, positive control), 201T lung tumor cells (negative control), VC-2, and DA-Src-5 cell lines. Each conditioned medium sample was concent
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00b75f740fb0e036dbd48f962ceea0b0
https://doi.org/10.1158/1078-0432.22454877
Zobrazit plný text záznamu
6
Supplementary Figure 1 from c-Src Activation Mediates Erlotinib Resistance in Head and Neck Cancer by Stimulating c-Met
Autor: Jennifer R. Grandis, Jill M. Siegfried, Kelly M. Quesnelle, Sonali Joyce, Christopher T. Gubish, Cassandra Henry, Sufi M. Thomas, Vivian Wai Yan Lui, Guoqing He, Laura P. Stabile
PDF file - 31K, DA-Src cells and VC cells had similar sensitivity towards cisplatin treatment. Cells were treated with cisplatin (0.1μM, 1.0μM and 5.0μM) for 72 hrs, followed by MTT assay. Cumulative data from 3 independent experiments are shown.
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9dbc151caa1323cd3e61d45915435505
https://doi.org/10.1158/1078-0432.22454880.v1
Zobrazit plný text záznamu
7
Data from Dual Blockade of EGFR and c-Met Abrogates Redundant Signaling and Proliferation in Head and Neck Carcinoma Cells
Autor: Jill M. Siegfried, Jennifer R. Grandis, William E. Gooding, Christopher T. Gubish, Laura P. Stabile, Hai Xu
Purpose: Head and neck squamous cell carcinoma (HNSCC) is usually fatal, and innovative approaches targeting growth pathways are necessary to effectively treat this disease. Both the epidermal growth factor receptor (EGFR) and the hepatocyte growth f
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f8ad13118ae54aa37a157503d6ff0ff
https://doi.org/10.1158/1078-0432.c.6519590
Zobrazit plný text záznamu
8
Data from c-Src Activation Mediates Erlotinib Resistance in Head and Neck Cancer by Stimulating c-Met
Autor: Jennifer R. Grandis, Jill M. Siegfried, Kelly M. Quesnelle, Sonali Joyce, Christopher T. Gubish, Cassandra Henry, Sufi M. Thomas, Vivian Wai Yan Lui, Guoqing He, Laura P. Stabile
Purpose: Strategies to inhibit the EGF receptor (EGFR) using the tyrosine kinase inhibitor erlotinib have been associated with limited clinical efficacy in head and neck squamous cell carcinoma (HNSCC). Co-activation of alternative kinases may contri
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1046ebc0f1183814d764d43189a5926e
https://doi.org/10.1158/1078-0432.c.6522858.v1
Zobrazit plný text záznamu
10
Combining the Multitargeted Tyrosine Kinase Inhibitor Vandetanib with the Antiestrogen Fulvestrant Enhances Its Antitumor Effect in Non-small Cell Lung Cancer
Autor: Jill M. Siegfried, Cassandra Henry, Christopher T. Gubish, Laura P. Stabile, Mary E. Rothstein
Publikováno v: Journal of Thoracic Oncology. 7:485-495
IntroductionEstrogen is known to promote proliferation and to activate the epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC). Vascular endothelial growth factor (VEGF) is a known estrogen responsive gene in breast cancer.
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df3ab912777c70ca8f90025a006604ce
https://doi.org/10.1097/jto.0b013e31824177ea
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje